Datamonitor, Dec 2010, Pages: 53
how the acquisition of MerckKGaA's generics unit continues to re-shape Mylan's business
Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2005
Datamonitor, Dec 2010, Pages: 62
Merck & Co., Inc.
MerckKGaA
New River Pharmaceuticals Inc.
New York & Company, Inc.
Novartis AG
Noven Pharmaceuticals Inc
Novo Nordisk A/S
Nycomed International Management GmbH
Sepracor Inc
Datamonitor, Oct 2010, Pages: 98
Lilly and Company
GlaxoSmithKline Plc
IMS Health
Ligand Pharmaceuticals Incorporated
Medicines Company, The
Merck & Co., Inc.
MerckKGaA
Novartis AG
Pfizer Inc
Tanabe Seiyaku Co., Ltd.
TAP
Datamonitor, March 2011, Pages: 84
Communications Company, Inc.
Johnson & Johnson
Medarex Inc
Merck & Co., Inc.
MerckKGaA
New York & Company, Inc.
Novartis AG
NYSE Euronext
Pfizer Inc
Sanofi-Aventis
Wyeth Bristol-Myers Squibb Co
Datamonitor, March 2009
to Purchase
- Benchmark Mylan's performance against key rivals in the prescription pharmaceutical sector
- Assess how the acquisition of MerckKGaA's generics division will impact Mylan's forecast performance